Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Risk adjusted net present value: What is the current valuation of Lantheus's Lutetium (177Lu) Zadavotide Quraxetan?
Lutetium (177Lu) Zadavotide Quraxetan is a small molecule commercialized by Lantheus, with a leading Phase III program in Metastatic Castration-Resistant...